Article

In the Pipeline for Psoriasis: Upcoming Psoriasis Treatments
Psoriasis is a chronic debilitating disease in which dermatologists take a frontline role in improving the quality of life of affected patients....
George Han, MD, PhD
Biologic agents, or protein-based drugs derived from living cells, are becoming commonplace in dermatology for the treatment of psoriasis, but their use spans many dermatologic conditions beyond psoriasis and psoriatic arthritis. In recent years, there has been considerable interest in their use for other inflammatory skin diseases. This article will review currently available data and reports on the off-label use of biologics in the treatment of cutaneous diseases other than psoriasis, including inflammatory dermal processes, autoimmune bullous skin diseases, connective-tissue diseases, and hidradenitis suppurativa (HS).
Psoriasis is a chronic debilitating disease in which dermatologists take a frontline role in improving the quality of life of affected patients....
The passage of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) allowed for the creation of a regulatory pathway for new,...
Dr. Jashin Wu discusses combination therapy with tumor necrosis factor inhibitors for psoriasis.